Background In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced
disease progression, as measured by the decline in forced vital capacity (FVC) or vital …

Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with inevitable
loss of lung function. The CAPACITY programme (studies 004 and 006) was designed …

Acute respiratory distress syndrome (ARDS) in COVID-19 is associated with high mortality.
Mesenchymal stem cells are known to exert immunomodulatory and anti-inflammatory effects …

Although the cellular functions ofTSC2 and its protein product, tuberin, are not known, somatic
mutations in the TSC2 tumor suppressor gene are associated with tumor development in …

Pirfenidone is an antifibrotic agent that has been evaluated in three multinational phase 3
trials in patients with idiopathic pulmonary fibrosis (IPF). We analysed pooled data from the …

Background In clinical trials of idiopathic pulmonary fibrosis, rates of all-cause mortality are
low. Thus prospective mortality trials are logistically very challenging, justifying the use of …

Large multicenter clinical trials have led to two recently approved drugs for patients with
idiopathic pulmonary fibrosis (IPF); yet, both of these therapies only slow disease progression …

Background Interstitial lung disease is a known complication of rheumatoid arthritis, with a
lifetime risk of developing the disease in any individual of 7·7%. We aimed to assess the safety…

… Author links open overlay panel Marilyn K. Glassberg MD a b c , Julia Minkiewicz PhD a ,
Rebecca L. Toonkel MD d , Emmanuelle S. Simonet MA a , Gustavo … K. Le Blanc, F. Frassoni, L. …

Background The assessment of treatment response in idiopathic pulmonary fibrosis (IPF) is
complicated by the variable clinical course. We examined the variability in the rate of disease …